title: Recurrent Stroke while on Antiplatelet Therapy.
abstract: Of the ≈795,000 strokes in the United States annually, 185,000 are recurrent. A third to half of them occur while on antiplatelet therapy. Multiple reasons could explain breakthrough stroke while on antiplatelet therapy. Management of recurrent stroke requires a meticulous search for the cause and mechanism of stroke. At present, there is no indication for antiplatelet resistance testing in ischemic stroke, or adjusting medications based on its results. Recent trials have shown the effectiveness of dual antiplatelet therapy in the acute period after an ischemic event, but no benefit has been found with this regimen for long-term secondary prevention.
authors.affiliation: Cerebrovascular Center, Cleveland Clinic, 9500 Euclid Avenue, S80, Cleveland, OH 44195, USA.
authors.forename: Seby
authors.initials: S
authors.lastname: John
authors.affiliation: Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, 9500 Euclid Avenue, S80, Cleveland, OH 44195, USA. Electronic address: katzani@ccf.org.
authors.forename: Irene
authors.initials: I
authors.lastname: Katzan
mesh_terms: D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: Antiplatelets; Ischemic stroke; Recurrence; Resistance; Treatment failure